Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 5/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 9/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17685060 | 0.85 | MAPT (0.55) | TP53MAPTTHRBLMNAAHR | |
| SCHEMBL3325920 | 0.84 | MAPT (0.46) | TP53MAPTTHRBLMNAAHR | |
| SCHEMBL17354603 | 0.82 | MAPT (0.52) | TP53MAPTTHRBLMNAAHR | |
| SCHEMBL3325933 | 0.79 | MAPT (0.60) | TP53MAPTTHRBLMNAAHR | |
| SCHEMBL3323549 | 0.77 | MAPT (0.75) | TP53MAPTTHRBLMNA | |
| SCHEMBL3323176 | 0.76 | MAPT (0.64) | TP53MAPTTHRBLMNAAHR | |
| SCHEMBL3325860 | 0.75 | MAPT (0.60) | TP53MAPTTHRBLMNAAHR | |
| SCHEMBL17689834 | 0.74 | PTGER1 (0.33) | TP53MAPTTHRBLMNALDHA | |
| SCHEMBL3322493 | 0.74 | MAPT (0.59) | TP53MAPTTHRBLMNALDHA | |
| SCHEMBL2997463 | 0.74 | ALDH1A1 (0.46) | MAPTLMNALDHAPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970118-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2018-09-12 | — | — | EP | claimed |
| EP-2813498-B1 | Compounds for Alzheimer's disease | MANFREDI JOHN (US) | 2016-04-20 | — | — | EP | claimed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | claimed |
| EP-2813498-A1 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2014-12-17 | — | — | EP | claimed |
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2013-10-03 | — | — | US | claimed |
| CN-101068781-B | Compounds for alzheimer's disease | MYRIAD GENETICS, INC. (US) | 2012-02-01 | — | — | CN | claimed |
| EP-2970118-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2813498-B1 | Compounds for Alzheimer's disease | MANFREDI JOHN (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-2139472-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | SLC18A2, SLC18A3, NLN | TP53 2751/4885MAPT 10/4885THRB 2651/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | TP53 306/4885MAPT 46/4885THRB 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.